DOSSETT JEFFREY

Chief Revenue Officer Dossett sells 15,000 shares (−18.7% of holdings) across 11 transactions for $2.8M at blended avg $187.31

Jeffrey Dossett, Chief Revenue Officer of Impinj Inc, executed 11 separate sales totaling 15,000 shares for $2,809,589.25, reducing his holdings from 80,294 to 65,294 shares. The transactions occurred over two trading days (Nov 13–14, 2024) at prices ranging from $179.29 to $195.83, near the 52-week high of $238.58. While Dossett's cross-ticker track record shows an average 90-day return of +25.1% following his prior sales, his prior trades at Impinj (5 historical sales all on 2024-08-01) were poorly timed, posting positive 90-day returns averaging +23.1%, indicating the stock rose after his August sales. The company's fundamentals show revenue growth of +19.3% year-over-year with current-quarter revenue of $95,198,000.00, though net income was minimal ($221,000.00 in the latest quarter) and the full-year was unprofitable. The stock has declined 21.7% in the past 30 days and is down 23.4% from its 52-week high, despite the 13.6% gain over 90 days.

CRO DOSSETT sells 30,000 shares (30.0K shares) for $4,639,393.54 across 19 transactions over two days.

Jeffrey Dossett, Chief Revenue Officer of Impinj Inc, executed 19 separate sales totaling 30,000 shares for $4,639,393.54 at a blended average price of $154.65 between July 31 and August 1, 2024, reducing his holdings from 93.6K shares to 63.6K shares (-32.0%). The multi-day, multi-tranche structure suggests a systematic liquidation rather than a single opportunistic exit. The stock has declined -23.2% from its 52-week high of $181.50 and is currently trading at $139.34, -12.8% down over the past 30 days. His prior sales at Impinj showed poor 90-day timing (all five prior trades resulted in positive returns, meaning the stock rose after he sold), though this filing's timing relative to subsequent performance cannot yet be assessed. The company's elevated P/E of 316.68 against negative full-year profitability and a market cap of $3.9B provides context for valuation concerns that may motivate a CRO's portfolio reduction.